Overview

Study of RAD001 in Adenoid Cystic Carcinoma

Status:
Completed

Trial end date:
2012-12-01

Target enrollment:

Participant gender:

Summary

- Although mTOR is clearly an attractive therapeutic target in tumor, no clinical study on mTOR inhibition by RAD001 has been systematically conducted in adenoid cystic carcinoma. - In phase I study of RAD001, 2 patients with adenoid cystic carcinoma show some response to RAD001 (unpublished data). - So the investigators design this phase II study of RAD001 in adenoid cystic carcinoma to evaluate the efficacy of RAD001 in this orphan disease.

Phase:

Phase 2

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Everolimus
Sirolimus